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A total of seven novel benzimidazoles were synthesized by a 4-step reaction starting from 4-fluoro-3-nitrobenzoic acid under
relativelymild reaction conditions.The synthesized compounds were screened for their antimycobacterial activity againstM. tuber-
culosis H
37
Rv (MTB-H
37
Rv) and INH-resistant M. tuberculosis (INHR-MTB) strains using agar dilution method. Three of them
displayed good activity with MIC of less than 0.2𝜇M. Compound ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-aminophenyl)piperazin-1-
yl)ethyl)-2-(4-(5-(4-fluorophenyl)pyridin-3-ylphenyl-1H-benzo[d]imidazole-5-carboxylate (5g) was found to be the most active
with MIC of 0.112𝜇M against MTB-H
37
Rv and 6.12 𝜇M against INHR-MTB, respectively.
1. Introduction
Tuberculosis (TB) is the oldest documented infectious dis-
ease. It is the only disease which does not require any
vector for transportation from one person to another [1].
The primary site of infection is the lungs, followed by
dissemination via the circulatory and lymphatic system to
secondary sites including the bones, joints, liver, and spleen.
In 2010, there were 8.8 million (range: 8.5–9.2 million)
incident cases of TB, 1.1 million (range: 0.9–1.2 million)
deaths from TB among HIV-negative people, and an addi-
tional 0.35 million (range: 0.32–0.39 million) deaths from
HIV-associated TB [2]. The introduction of the first-line
drugs like streptomycin, para-aminosalicylic acid, and iso-
niazid for treatment some 50 years ago has witnessed a
remarkable decline in TB cases all over the world. The active
TB is currently treated with a four-first-line-drug regimen
comprising mainly isoniazid, rifampicin, pyrazinamide, and
ethambutol for a period of at least 6 months [3, 4]. However,
the disease has been undergoing a resurgence in the last two
decades driven by variety of changes in social, medical, and
economic factors as well as M. tuberculosis resistance to the
aforementioned drugs itself.
The resurgence of TB is now one of the most serious
public health concerns worldwide. Despite its global impact
on world health, TB is considered a neglected disease, and
no new anti-TB therapeutics have been introduced into the
market over the last half-century. The last drug with a new
mechanism of action approved (rifampicin) was discovered
in 1963 [5].Therefore there is an urgent need for development
of new drug leads to combat this chronic infectious disease.
The benzimidazole nucleus is of significant importance
in medicinal chemistry research, and many benzimidazole-
containing compounds exhibit important biological proper-
ties such as antiviral [6], anti-inflammatory [7], and anti-HIV
[8]. In the light of the affinity they display towards a variety
of enzymes and protein receptors, medicinal chemists thus
classify them as “privileged substructures” for drug design [9].
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Table 1: Physical properties and analytical results of compounds 5a–g.
COOCH2CH3
N
N
N
N
R1
H3CH2COOC NH2
5a–g
Compound R
1
Formula C/H/N calculated(C/H/N found) [M + H] Yield (%)
5a C31H35N5O4
68.74%/6.51%/12.93%
(68.61%/6.45%/13.12%) 514.2 63
5b Cl C31H34N5O4Cl
64.63%/5.95%/12.16%
(64.45%/5.93%/12.25%) 575.2 85
5c
OH
HO
C31H35N5O6
64.91%/6.15%/12.21%
(64.72%/6.07%/12.40%) 573.3 71
5d OCF3 C32H34N5O5F3
61.43%/5.48%/11.19%
(61.55%/5.40%/11.22%) 625.3 90
5e CH3 C32H37N5O5
67.23%/6.52%/12.25%
(67.06%/6.42%/12.48%) 571.3 79
5f O
O
C32H35N5O6
65.63%/6.02%/11.96%
(65.62%/6.02%/11.92%) 585.3 73
5g
N
F
C42H41N6O4F
70.77%/5.80%/11.79%
(70.52%/5.72%/12.08%) 712.3 66
Recently, there has been reported work done on utilizing
benzimidazole derivatives to counter TB with relatively good
results [10–12], thus further reinforcing our belief that benz-
imidazole could potentially be a lead compound in our effort
to discover new potent anti-TB agents. In the present paper,
wewish to report the synthesis and antimycobacterial activity
of novel 2-substituted benzimidazole derivatives.
2. Materials and Methods
2.1. Chemistry. All chemicals were supplied by Sigma-
Aldrich (USA) and Merck Chemicals (Germany). Purity of
the compounds was checked on thin layer chromatography
(TLC) plates (silica gel G) in the solvent system chloroform-
methanol (9 : 1). The spots were located under short
(254 nm)/long (365 nm) UV light. Elemental analyses
were performed on Perkin Elmer 2400 Series II CHN
Elemental Analyzer and were within ±0.4% of the calculated
values. Physical properties and elemental analysis results of
compounds (Table 1). 1H and 13C NMR were performed on
Bruker Avance 300 (1H: 300MHz, 13C: 75MHz) spectro-
meter in CDCl
3
using TMS as internal standard (Table 2).
Mass spectra were recorded on Varian 320-MS TQ LC/MS
using ESI.
2.1.1. Procedure for the Preparation of Ethyl-4-fluoro-3-nitro-
benzoate (1). 4-Fluoro-3-nitrobenzoic acid (5 g, 27mmol)
was refluxed in ethanol (50mL) and concentrated H
2
SO
4
(2mL) for 8 hours. After completion of reaction (as evi-
dent from TLC), the solvent was evaporated under reduced
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Table 2: 1H NMR results for compounds 1, 2, and 5a–g and selected 13C NMR results.
Compound NMR (𝛿 ppm)
Ethyl-4-fluoro-3-nitrobenzoate, 1
1H NMR: 1.44 (3H, t, 𝐽 = 7.2Hz), 4.45 (2H, q, 𝐽 = 7.2Hz), 7.41 (1H, d, 𝐽 =
8.4Hz), 8.70 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.89 (1H, s)
Ethyl 3-amino-4-(4-(2-((4-(ethoxycarbonyl)-2-
nitrophenyl)amino)ethyl)piperazin-1-yl)benzoate, 2
1H NMR: 1.38 (3H, t, 𝐽 = 7.2Hz), 1.43 (3H, t, 𝐽 = 7.2Hz), 2.79 (4H, t, 𝐽 =
4.8Hz), 2.90 (2H, t, 𝐽 = 6.9Hz), 3.29 (4H, t, 𝐽 = 4.8Hz), 3.52 (2H, q, 𝐽 =
7.2Hz), 4.37 (2H, t, 𝐽 = 6.9Hz), 4.44 (2H, q, 𝐽 = 7.2Hz), 6.87 (1H, d, 𝐽 =
8.4Hz), 7.11 (1H, d, 𝐽 = 8.4Hz), 8.15 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.33 (1H,
dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.74 (1H, s), 8.84 (1H, s)
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-
aminophenyl)piperazin-1-yl)ethyl)-2-phenyl-1H-
benzo[d]imidazole-5-carboxylate, 5a
1H NMR: 1.37 (3H, t, 𝐽 = 7.2Hz), 1.44 (3H, t, 𝐽 = 7.2Hz), 2.53 (4H, t, 𝐽 =
4.8Hz), 2.85 (2H, t, 𝐽 = 6.9Hz), 3.91 (4H, t, 𝐽 = 4.8Hz), 4.35 (2H, q, 𝐽 =
7.2Hz), 4.45 (2H, t, 𝐽 = 6.9Hz), 4.46 (2H, q, 𝐽 = 7.2Hz), 6.90–7.20 (5H, m),
7.50 (1H, d, 𝐽 = 8.4Hz), 8.11 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.57 (1H, s)
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-
aminophenyl)piperazin-1-yl)ethyl)-2-(4-chlorophenyl)-
1H-benzo[d]imidazole-5-carboxylate, 5b
1H NMR: 1.38 (3H, t, 𝐽 = 7.2Hz), 1.46 (3H, t, 𝐽 = 7.2Hz), 2.54 (4H, t, 𝐽 =
4.8Hz), 2.86 (2H, t, 𝐽 = 6.9Hz), 3.91 (4H, t, 𝐽 = 4.8Hz), 4.35 (2H, q, 𝐽 =
7.2Hz), 4.45 (2H, t, 𝐽 = 6.9Hz), 4.46 (2H, q, 𝐽 = 7.2Hz), 6.92 (1H, d, 𝐽 =
8.4Hz), 7.40 (1H, s), 7.47 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 7.52 (1H, d, 𝐽 =
8.4Hz), 7.65 (2H, d, 𝐽 = 8.4Hz), 7.85 (2H, d, 𝐽 = 8.4Hz), 8.12 (1H, dd, 𝐽
1
=
8.4Hz, 𝐽
2
= 1.5Hz), 8.58 (1H, s)
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-
aminophenyl)piperazin-1-yl)ethyl)-2-(2,
4-dihydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylate, 5c
1H NMR: 1.37 (3H, t, 𝐽 = 7.2Hz), 1.44 (3H, t, 𝐽 = 7.2Hz), 2.53 (4H, t, 𝐽 =
4.8Hz), 2.85 (2H, t, 𝐽 = 6.9Hz), 3.91 (4H, t, 𝐽 = 4.8Hz), 4.35 (2H, q, 𝐽 =
7.2Hz), 4.44 (2H, t, 𝐽 = 6.9Hz), 4.45 (2H, q, 𝐽 = 7.2Hz), 6.68 (1H, s), 6.87 (1H,
dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 6.92 (1H, d, 𝐽 = 8.4Hz), 7.40 (1H, s), 7.44 (1H, d,
𝐽 = 8.4Hz), 7.50 (1H, d, 𝐽 = 8.4Hz), 7.56 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.16
(1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.56 (1H, s)
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-amino-
phenyl)piperazin-1-yl)ethyl)-2-(4-(trifluoro-
methoxy)phenyl)-1H-benzo[d]imidazole-5-
carboxylate, 5d
1H NMR: 1.38 (3H, t, 𝐽 = 7.2Hz), 1.46 (3H, t, 𝐽 = 7.2Hz), 2.53 (4H, t, 𝐽 =
4.8Hz), 2.85 (2H, t, 𝐽 = 6.9Hz), 3.91 (4H, t, 𝐽 = 4.8Hz), 4.35 (2H, q, 𝐽 =
7.2Hz), 4.45 (2H, t, 𝐽 = 6.9Hz), 4.46 (2H, q, 𝐽 = 7.2Hz), 6.92 (1H, d, 𝐽 =
8.4Hz), 7.40 (1H, s), 7.47 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 7.52 (1H, d, 𝐽 =
8.4Hz), 7.66 (2H, d, 𝐽 = 8.4Hz), 7.84 (2H, d, 𝐽 = 8.4Hz), 8.12 (1H, dd, 𝐽
1
=
8.4Hz, 𝐽
2
= 1.5Hz), 8.59 (1H, s)
13C NMR: 14.78, 43.48, 50.46, 54.47, 57.53, 61.08, 61.41, 110.28, 114.00, 116.46,
119.19, 120.97, 122.20, 125.92, 126.19, 126.23, 126.72, 134.17, 139.17, 141.08, 143.09,
143.32, 154.48, 160.05, 167.13, 167.36
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-
aminophenyl)piperazin-1-yl)ethyl)-2-p-tolyl-1H-
benzo[d]imidazole-5-carboxylate, 5e
1H NMR: 1.37 (3H, t, 𝐽 = 7.2Hz), 1.45 (3H, t, 𝐽 = 7.2Hz), 2.53 (4H, t, 𝐽 =
4.8Hz), 2.85 (2H, t, 𝐽 = 6.9Hz), 3.91 (4H, t, 𝐽 = 4.8Hz), 4.35 (2H, q, 𝐽 =
7.2Hz), 4.45 (2H, t, 𝐽 = 6.9Hz), 4.46 (2H, q, 𝐽 = 7.2Hz), 4.48 (3H, s), 6.90 (1H,
d, 𝐽 = 8.4Hz), 7.40 (1H, s), 7.46 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 7.52 (1H, d,
𝐽 = 8.4Hz), 7.66 (2H, d, 𝐽 = 8.4Hz), 7.84 (2H, d, 𝐽 = 8.4Hz), 8.12 (1H, dd, 𝐽
1
=
8.4Hz, 𝐽
2
= 1.5Hz), 8.57 (1H, s)
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-
aminophenyl)piperazin-1-yl)ethyl)-2-(benzo[d][1,
3]dioxol-5-yl)-1H-benzo[d]imidazole-5-carboxylate, 5f
1H NMR: 1.38 (3H, t, 𝐽 = 7.2Hz), 1.46 (3H, t, 𝐽 = 7.2Hz), 2.53 (4H, t, 𝐽 =
4.8Hz), 2.85 (2H, t, 𝐽 = 6.9Hz), 3.90 (4H, t, 𝐽 = 4.8Hz), 4.35 (2H, q, 𝐽 =
7.2Hz), 4.45 (2H, t, 𝐽 = 6.9Hz), 4.46 (2H, q, 𝐽 = 7.2Hz), 6.10 (2H, s), 6.92 (1H,
d, 𝐽 = 8.4Hz), 7.40 (1H, s), 7.47 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 7.35 (1H, d, 𝐽 =
8.4Hz), 7.45–7.55 (3H, m), 8.08 (1H, dd, 𝐽
1
= 8.4Hz, 𝐽
2
= 1.5Hz), 8.55 (1H, s)
Ethyl 1-(2-(4-(4-(ethoxycarbonyl)-2-amino-
phenyl)piperazin-1-yl)ethyl)-2-(4-(5-(4-
fluorophenyl)pyridin-3-yl)phenyl)-1H-
benzo[d]imidazole-5-carboxylate, 5g
1H NMR: 1.39 (3H, t, 𝐽 = 7.2Hz), 1.47 (3H, t, 𝐽 = 7.2Hz), 2.54 (4H, t, 𝐽 =
4.8Hz), 2.85 (2H, t, 𝐽 = 6.9Hz), 3.93 (4H, t, 𝐽 = 4.8Hz), 4.32 (2H, q, 𝐽 =
7.2Hz), 4.45 (2H, t, 𝐽 = 6.9Hz), 4.46 (2H, q, 𝐽 = 7.2Hz), 6.90–8.20 (10H, m),
8.59 (1H, s), 8.70 (2H, s)
pressure. The aqueous layer was extracted with ethyl acetate
(25mL × 3). The organic layer was dried over Na
2
SO
4
and
concentrated under reduced pressure to yield 1 as cream-
coloured powder (75%).
2.1.2. Procedure for the Preparation of Ethyl 3-amino-4-(4-(2-
((4-(ethoxycarbonyl)-2-nitrophenyl)amino)ethyl)piperazin-1-
yl)benzoate (2). Ethyl-4-fluoro-3-nitrobenzoate, 1 (0.5 g,
2.34mmol), N-(2-aminoethyl)piperazine (0.15mL, 1.16
mmol), and N,N-diisopropylethylamine (DIPEA) (0.49mL,
2.78mmol) were mixed in dichloromethane (10mL). The
reaction mixture was stirred overnight at room temperature.
After completion of reaction (as evident from TLC), the
reactionmixture was washed with water (10mL × 2) followed
by 10%Na
2
CO
3
solution (10mL).The organic layer was dried
over Na
2
SO
4
and concentrated under reduced pressure to
afford 2 as brown oil (91%).
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Table 3: Antimycobacterial activity of compounds 5a–g againstM.
tuberculosisH37Rv and INH-resistantMycobacterium tuberculosis.
COOCH2CH3
N
N
N
N
R1
H3CH2COOC NH2
5a–g
Compound MIC
a
(𝜇M)
MICb
(𝜇M)
6.12 cytotoxicity
(𝜇g/mL)
5a 6.219 64.78 >62.5
5b 0.195 24.12 >62.5
5c 4.320 26.12 >62.5
5d 0.135 16.25 >62.5
5e 6.195 2.10 >62.5
5f 6.219 41.72 >62.5
5g 0.112 6.12 >62.5
Isoniazid 0.73 11.37 >62.5
aMycobacterium tuberculosis H37Rv and bINH-resistant Mycobacterium
tuberculosis.
2.1.3. Procedure for the Preparation of Ethyl 3-amino-4-(4-(2-
((2-amino-4-(ethoxycarbonyl)phenyl)amino)ethyl)piperazin-
1-yl)benzoate (3). Ethyl 3-amino-4-(4-(2-((4-(ethoxycarbo-
nyl)-2-nitrophenyl)amino)ethyl)piperazin-1-yl)benzoate, 2
(0.486 g, 1mmol), ammonium formate (0.378 g, 6mmol),
and Pd/C (50mg) were mixed in ethanol (10mL). The reac-
tion mixture was refluxed until completion (solution turned
colourless). The reaction mixture was then filtered through
Celite 545. The filtrate was evaporated under reduced
pressure. It was resuspended in ethyl acetate and washed
with water, dried over Na
2
SO
4
, and evaporated to dryness to
yield 3 (70%).
2.1.4. General Procedure for the Preparation of SodiumBisulfite
Adducts of 4-Substituted Benzaldehyde (4a–g). Appropriate
benzaldehyde (10mmol) was dissolved in ethanol (20mL).
Sodium metabisulfite (15mmol) in 5mL water was added in
portion over 5 minutes. The reaction mixture was stirred at
room temperature for 1 hour and subsequently stirred at 4∘C
overnight. The precipitate formed was filtered and dried to
afford sodium bisulfite adducts (55%–90%).
2.1.5. General Procedure for the Preparation of 2-Substituted
Benzimidazole Derivatives (5a–g). Ethyl 3-amino-4-(4-(2-
((2-amino-4-(ethoxycarbonyl)phenyl)amino)ethyl) piperaz-
in-1-yl)benzoate, 3 (1mmol) and various sodium bisulfite
adducts, 4 (1.5mmol) were dissolved in DMF (5mL). The
reactionmixturewas stirred at 90∘CunderN
2
atmosphere for
24–48 hours. After completion of reaction (evident by TLC),
the reaction mixture was diluted in ethyl acetate (25mL)
and washed with water (10mL × 3). The organic layer was
collected, dried over Na
2
SO
4
, and evaporated under reduced
pressure to afford compounds 5a–g in 63–90% yields.
2.2. Biology. In vitro antimycobacterial activity of the com-
pounds was evaluated against Mycobacterium tuberculosis
H
37
Rv (MTB-H
37
Rv) using the broth dilution method
as reported by Collins and Franzblau [13]. The minimum
inhibitory concentration (MIC) values were determined
using M. tuberculosis (MTB-H
37
Rv) and INH-resistant M.
tuberculosis (INHR-MTB) strains. The MIC was defined as
theminimum concentration of compound required to inhibit
90% of bacterial growth.
3. Results and Discussion
3.1. Chemistry. Our synthetic study into novel benzimid–
azoles started with 4-fluoro-3-nitro benzoic acid which
was esterified in the presence of catalytic sulfuric acid in
ethanol by refluxing for 8 hours to afford ethyl-4-fluoro-
3-nitrobenzoate 1, in 75% yield. The ethylbenzoate 1 was
then treated with amine and DIPEA in dry dichloromethane
at room temperature to yield ethyl 3-amino-4-(4-(2-((4-
(ethoxycarbonyl)-2-nitrophenyl)amino)ethyl)piperazin-1-
yl)benzoate 2, which was then reduced to 3 using ammonium
formate and 10% Pd/C for 1 hour to give 70% yield.
The phenylenediamine 3 was then refluxed with various
substituted bisulfite adducts of aromatic aldehydes [14] in
DMF overnight to afford benzimidazole derivatives 5a–g in
moderate to good yields (63–90%).The structure of the novel
benzimidazoles was confirmed by chromatographic and
spectroscopic analysis. The mechanism for the formation
of the novel benzimidazole derivatives is proposed and
summarized in Scheme 1.
3.2. Pharmacology. A total of seven novel benzimidazole
derivatives were synthesized and then analyzed for their
antimycobacterial activities against Mycobacterium tubercu-
losis H
37
Rv (MTB-H
37
Rv) and INH-resistantM. tuberculosis
(INHR-MTB). Results are shown in Table 3 with standard
drug isoniazid as comparison.
We synthesized compounds with a wide range of substi-
tution including compounds with electron-donating as well
as electron-withdrawing groups. Generally, we found that
electron-withdrawing group substituents at 4-position in the
phenyl ring are important for good activities. Three com-
pounds (5b, 5d, and 5g) showed excellent potency against
MTB-H
37
Rv with MIC of <0.2 𝜇M. Of all 9 compounds
which have been tested, compound 5g was found to be the
most active with MIC of 0.112𝜇M against MTB-H
37
Rv and
6.12 𝜇M against INHR-MTB. This was followed by 5d (MIC
= 0.135 𝜇M against MTB-H
37
Rv and 16.25 𝜇M against INHR-
MTB) and 5b (MIC = 0.195 𝜇M against MTB-H
37
Rv and
24.12 𝜇M 6.12 against INHR-MTB). However the electron-
donating groups such as 2,4-dihydroxyl and 4-methoxyl sub-
stituted analogue compounds produced moderate inhibitory
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Pd/C
HO
DMF
COOH
F F
DIPEA, DCM
NH
1
2
Sodium
metabisulfite
Ethanol
Overnight, RT
N
N
HN
N
NH
N
N
3
N
N
N
N
4a–g
5a–g
NO2
COOCH2CH3
COOCH2CH3
COOCH2CH3
NH2
NH2H3CH2COOC
NO2
NO2
NO2
COOCH2CH3
H2SO4
NH2
NH2
H3CH2COOC
H3CH2COOC
C2H5OH
HCOONH4
R1
R1
SO3Na
90
∘C
R1–CHO
+−
Scheme 1: Protocol for synthesis of 5a–g.
activity againstMTBMycobacterium tuberculosis.This clearly
showed that the presence of electron-withdrawing group,
especially halogen substitution at 4-position of the phenyl
ring, caused marked improvement in antimycobacterial
activity.
All the compoundswere also tested for cytotoxicity (IC
50
)
in VERO cells at a concentration of 62.5𝜇g/mL. After 72 h
of exposure, viability was assessed on the basis of cellular
conversion of MTT into a formazan product using the
Promega CellTiter 96 nonradioactive cell proliferation assay
6 BioMed Research International
according to the manufacturer’s protocol. All of the active
compounds were found to be nontoxic till 62.5𝜇g/mL.
4. Conclusion
In conclusion, we have synthesized successfully a series of
novel benzimidazole derivatives with good antimycobacterial
properties againstM. tuberculosis. Encouraged by the positive
results we have reported here, further modification on the
4-position on the bisulfite adducts as well as quantita-
tive structure-activity relationship (QSAR) is currently in
progress in our laboratory. It is conceivable that derivatives
showing antimycobacterial activity can be further modified
to exhibit better potency than standard drugs.
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